Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aclaris Therapeutics, Inc.

NASDAQ: ACRS · Life Sciences · 5 alerts · CIK 1557746

Aclaris Therapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$3.61Close, Nov 16
Market cap
$572M
Shares outstanding
158.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aclaris Therapeutics, Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Clinical Trial Data

Aclaris Therapeutics Clinical Trial Data

Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis failed to meet its primary and secondary endpoints. Despite robust target engagement and biomarker downregulation, the company will shift focus toward its oral ITK inhibitors and bispecific antibody ATI-052. The company also announced the initiation of a Phase 2b trial for modzatinib in lichen planus and plans to file an IND for ATI-9494 in Q4 2026.

5:26 PM ET 8-K
Capital Raise

Aclaris Therapeutics Capital Raise of $50M

Aclaris Therapeutics entered into an underwriting agreement to sell 7,785,714 shares of common stock and pre-funded warrants for 6,500,000 shares at a price of $3.50 per share. The company expects to receive gross proceeds of approximately $50 million ($46.7 million net) to fund its operations. The offering is expected to close on October 28, 2026.

Value
$50M
Counterparty
Leerink Partners LLC
6:07 AM ET 8-K
Clinical Trial Data

Aclaris Therapeutics Clinical Trial Data

Aclaris Therapeutics announced positive Phase 1b proof-of-concept results for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in patients with atopic dermatitis and asthma. The data showed a 45% placebo-adjusted mean improvement in EASI scores for atopic dermatitis and rapid improvements in lung function for asthma patients, with a favorable safety profile and no observed conjunctivitis. The company plans to prioritize Phase 2b development of ATI-052 for eosinophilic esophagitis (EoE) starting in early 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.